| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Second Department of Medicine,* Research Center for Innovative Cancer Therapy, and Center of the 21st Century Center of Excellence Program for Medical Science, Kurume University School of Medicine, Kurume; and the Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyusyu University, Fukuoka, Japan
The pathogenesis of hepatitis C virus (HCV)-associated insulin resistance remains unclear. Therefore, we investigated mechanisms for HCV-associated insulin resistance. Homeostasis model assessment for insulin resistance was increased in patients with HCV infection. An increase in fasting insulin levels was associated with the presence of serum HCV core, the severity of hepatic fibrosis and a decrease in expression of insulin receptor substrate (IRS) 1 and IRS2, central molecules of the insulin-signaling cascade, in patients with HCV infection. Down-regulation of IRS1 and IRS2 was also seen in HCV core-transgenic mice livers and HCV core-transfected human hepatoma cells. Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, a potent proteosomal proteolysis inhibitor, blocked down-regulation of IRS1 and IRS2 in HCV core-transfected hepatoma cells. In human hepatoma cells, HCV core up-regulated suppressor of cytokine signaling (SOCS) 3 and caused ubiquitination of IRS1 and IRS2. HCV core-induced down-regulation of IRS1 and IRS2 was not seen in SOCS3–/– mouse embryonic fibroblast cells. Furthermore, HCV core suppressed insulin-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase and Akt, activation of 6-phosphofructo-2-kinase, and glucose uptake. In conclusion, HCV infection changes a subset of hepatic molecules regulating glucose metabolism. A possible mechanism is that HCV core-induced SOCS3 promotes proteosomal degradation of IRS1 and IRS2 through ubiquitination.
This article has been cited by other articles:
 |
|
 |
|
  P. P. Cox-North Re: The Relationship of Hepatitis Antibodies and Elevated Liver Enzymes with Impaired Fasting Glucose and Undiagnosed Diabetes J Am Board Fam Med, May 1, 2009; 22(3): 339 - 339. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Machida, H. Tsukamoto, H. Mkrtchyan, L. Duan, A. Dynnyk, H. M. Liu, K. Asahina, S. Govindarajan, R. Ray, J.-h. J. Ou, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog PNAS, February 3, 2009; 106(5): 1548 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi Hepatitis C Infection and Chronic Renal Diseases Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 207 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Banerjee, K. Saito, M. Ait-Goughoulte, K. Meyer, R. B. Ray, and R. Ray Hepatitis C Virus Core Protein Upregulates Serine Phosphorylation of Insulin Receptor Substrate-1 and Impairs the Downstream Akt/Protein Kinase B Signaling Pathway for Insulin Resistance J. Virol., March 15, 2008; 82(6): 2606 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Oben and E. Paulon Fatty liver in chronic hepatitis C infection: unravelling the mechanisms Gut, September 1, 2007; 56(9): 1186 - 1188. [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease Diabetes Care, March 1, 2007; 30(3): 734 - 743. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Crutchlow and R. D. Bloom Transplant-Associated Hyperglycemia: A New Look at an Old Problem Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Zekry, J G McHutchison, and A M Diehl Insulin resistance and steatosis in hepatitis C virus infection Gut, July 1, 2005; 54(7): 903 - 906. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
